ArticleThe American journal of gastroenterology2009
Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study.
Article in The American journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 3 syntheses or guidelines pooled it, 419 citations in OpenAlex.
- Incidence of thrombosis in patients with hepatocellular carcinoma: systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2025Pooled it
- Epidemiology of venous thromboembolism in patients with liver diseases: a systematic review and meta-analysis.Internal and emergency medicine · 2015Pooled it
- Deep vein thrombosis and pulmonary embolism in cirrhotic patients: systematic review.World journal of gastroenterology · 2014Pooled it
- Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis.Clinical and molecular hepatology · 2014Trial
- Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.JHEP reports : innovation in hepatology · 2026Article
- Association of Early Heparin Use with Mortality in Cirrhotic Patients: A Retrospective Cohort Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Case Report: Nonoperative management of traumatic dual-vessel hepatic infarction.Frontiers in surgery · 2026Article
- Direct oral anticoagulants in patients with advanced cirrhosis: is it time?Research and practice in thrombosis and haemostasis · 2026Article
- Thrombin dynamics and clinical events in cirrhosis: low prothrombin conversion predicts bleeding risk.Frontiers in cell and developmental biology · 2026Article
- Phytonadione Utilization and the Risk of Bleeding in Chronic Liver Disease.Hospital pharmacy · 2024Article
- Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis.Journal of thrombosis and haemostasis : JTH · 2024Article
- Hematological abnormalities in liver cirrhosis.World journal of hepatology · 2024Review
- Impact of Cirrhosis Etiology on the Risk for Venous Thromboembolism.Digestive diseases and sciences · 2024Observational
- Serum albumin, genetic susceptibility, and risk of venous thromboembolism.Research and practice in thrombosis and haemostasis · 2024Article
- Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.JHEP reports : innovation in hepatology · 2024Article
- The Challenge of Anticoagulation in Liver Cirrhosis.Visceral medicine · 2024Review
- Interpretable machine learning models for predicting venous thromboembolism in the intensive care unit: an analysis based on data from 207 centers.Critical care (London, England) · 2023Article
- Imaging in hepatopulmonary syndrome-case report. A multicenter approach during the coronavirus pandemic.Journal of radiology case reports · 2023Article
- Association of nonalcoholic fatty liver disease and venous thromboembolic disease in healthy adults in Korea: a nationwide study.Scientific reports · 2023Article
- The Yin and the Yang of Hemostasis in End-Stage Liver Disease.Journal of clinical medicine · 2023Review
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIt is known that liver disease can cause an imbalance in the coagulation system, but available data on liver disease and risk of venous thromboembolism are conflicting. We examined the risk of venous thromboembolism in patients hospitalized with liver diseases.
methodsWe conducted a nationwide Danish case-control study of incident cases of venous thromboembolism from 1980 to 2005 using population-based data from the National Registry of Patients, and from the Civil Registration System. We used conditional logistic regression to compute the relative risk of venous thromboembolism in patients with liver disease compared to population controls. We then excluded patients with known malignancy (diagnosed either before or up to 3 months after the venous thromboembolism) or fractures, trauma, surgery, or pregnancy within 90 days before the venous thromboembolism to estimate the risk associated with unprovoked venous thromboembolism.
resultsA total of 99,444 patients with venous thromboembolism and 496,872 population controls were included in the study. Patients with liver disease had a clearly increased relative risk of venous thromboembolism, varying from 1.74 (95% CI, 1.54-1.95) for liver cirrhosis to 1.87 (95% CI, 1.73-2.03) for non-cirrhotic liver disease. The risks were higher for deep venous thrombosis compared with pulmonary embolism. In the analysis, restricted to 67,519 patients with unprovoked venous thromboembolism and 308,614 population controls, we found slightly higher relative risks: 2.06 (95% CI, 1.79-2.38) for liver cirrhosis and 2.10 (95% CI, 1.91-2.31) for non-cirrhotic liver disease.
conclusionsPatients with liver disease have a substantially increased risk of venous thromboembolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.